Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Cancel Tassin

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]R Renard-Penna, G Cancel Tassin, E Comperat, et al.
European Urology|September 18, 2002
A candidate gene approach within the susceptibility region PCaP on 1q42.2-43 excludes deleterious mutations of the PCTA-1 gene to be responsible for hereditary prostate cancerC Maier, K Rösch, K Herkommer, et al.
Bulletin Du Cancer|January 12, 2011
[Strategies for early diagnosis and prevention of prostate cancer]A Valeri, B Malavaud, O Desrichard, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]T Seisen, M Rouprêt, D Brault, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]T Seisen, M Rouprêt, G Cancel Tassin, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 5, 2017
[Prevalence and diversity of management of prostate cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study]P Léon, G Cancel-Tassin, N Koutlidis, et al.
Diagnostic and Interventional Imaging|March 24, 2017
Comparison of semi-automated and manual methods to measure the volume of prostate cancer on magnetic resonance imagingL Marin, M Ezziane, E Comperat, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 4, 2017
[Correlation of genetic and cytogenetic alterations in pathological aggressiveness urothelial carcinoma of the bladder: Performance of BCA-1, a mini-array comparative genomic hybridisation-based test]P Léon, G Cancel Tassin, K Sighar, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]P Léon, N Kloutidis, J Calves, et al.
Clinical Nutrition ESPEN|March 25, 2022
Screening, diagnosis and monitoring of sarcopenia: When to use which tool?Leanne L G C Ackermans, Joyce Rabou, M Basrai, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]R Renard-Penna, G Cancel Tassin, E Comperat, et al.
European Urology|September 18, 2002
A candidate gene approach within the susceptibility region PCaP on 1q42.2-43 excludes deleterious mutations of the PCTA-1 gene to be responsible for hereditary prostate cancerC Maier, K Rösch, K Herkommer, et al.
Bulletin Du Cancer|January 12, 2011
[Strategies for early diagnosis and prevention of prostate cancer]A Valeri, B Malavaud, O Desrichard, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]T Seisen, M Rouprêt, D Brault, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]T Seisen, M Rouprêt, G Cancel Tassin, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 5, 2017
[Prevalence and diversity of management of prostate cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study]P Léon, G Cancel-Tassin, N Koutlidis, et al.
Diagnostic and Interventional Imaging|March 24, 2017
Comparison of semi-automated and manual methods to measure the volume of prostate cancer on magnetic resonance imagingL Marin, M Ezziane, E Comperat, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 4, 2017
[Correlation of genetic and cytogenetic alterations in pathological aggressiveness urothelial carcinoma of the bladder: Performance of BCA-1, a mini-array comparative genomic hybridisation-based test]P Léon, G Cancel Tassin, K Sighar, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]P Léon, N Kloutidis, J Calves, et al.
Clinical Nutrition ESPEN|March 25, 2022
Screening, diagnosis and monitoring of sarcopenia: When to use which tool?Leanne L G C Ackermans, Joyce Rabou, M Basrai, et al.
Pageof 3